HK1099755A1 - Crystalline pyrazole derivative - Google Patents

Crystalline pyrazole derivative

Info

Publication number
HK1099755A1
HK1099755A1 HK07105647.9A HK07105647A HK1099755A1 HK 1099755 A1 HK1099755 A1 HK 1099755A1 HK 07105647 A HK07105647 A HK 07105647A HK 1099755 A1 HK1099755 A1 HK 1099755A1
Authority
HK
Hong Kong
Prior art keywords
pyrazole derivative
crystalline
crystalline pyrazole
derivative
pyrazole
Prior art date
Application number
HK07105647.9A
Other languages
English (en)
Inventor
Calvin Changquan Sun
Garry O'connor
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of HK1099755A1 publication Critical patent/HK1099755A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W16/00—Network planning, e.g. coverage or traffic planning tools; Network deployment, e.g. resource partitioning or cells structures
    • H04W16/18—Network planning tools
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W24/00—Supervisory, monitoring or testing arrangements
    • H04W24/02—Arrangements for optimising operational condition

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK07105647.9A 2004-04-01 2007-05-29 Crystalline pyrazole derivative HK1099755A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55846904P 2004-04-01 2004-04-01
PCT/IB2005/000735 WO2005095349A1 (fr) 2004-04-01 2005-03-21 Derives de pyrazoles cristallins

Publications (1)

Publication Number Publication Date
HK1099755A1 true HK1099755A1 (en) 2007-08-24

Family

ID=34961629

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105647.9A HK1099755A1 (en) 2004-04-01 2007-05-29 Crystalline pyrazole derivative

Country Status (25)

Country Link
US (2) US7652149B2 (fr)
EP (1) EP1742922B1 (fr)
JP (1) JP4177883B2 (fr)
KR (1) KR100820511B1 (fr)
CN (1) CN1938276B (fr)
AR (1) AR048449A1 (fr)
AU (1) AU2005227745C1 (fr)
BR (1) BRPI0509506A8 (fr)
CA (1) CA2562104C (fr)
DK (1) DK1742922T3 (fr)
EA (1) EA008697B1 (fr)
ES (1) ES2565409T3 (fr)
HK (1) HK1099755A1 (fr)
HU (1) HUE028811T2 (fr)
IL (1) IL177711A0 (fr)
MA (1) MA28494B1 (fr)
NO (1) NO20064986L (fr)
NZ (1) NZ550907A (fr)
PL (1) PL1742922T3 (fr)
SI (1) SI1742922T1 (fr)
TN (1) TNSN06313A1 (fr)
TW (1) TW200536816A (fr)
UA (1) UA84455C2 (fr)
WO (1) WO2005095349A1 (fr)
ZA (1) ZA200607154B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550907A (en) * 2004-04-01 2010-10-29 Pharmacia & Upjohn Co Llc Crystalline pyrazole derivative with COX-2 inhibitory activity for treating inflammation
CA2630849C (fr) * 2005-12-14 2013-05-14 Makhteshim Chemical Works Ltd. Polymorphes et formes amorphes de 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile
UA110598C2 (uk) 2006-11-10 2016-01-25 Басф Се Спосіб одержання кристалічної модифікації фіпронілу
ATE513470T1 (de) 2006-11-10 2011-07-15 Basf Se Kristalline fipronil-modifikation
KR101540122B1 (ko) 2006-11-10 2015-07-28 바스프 에스이 피프로닐의 결정질 변형물
JP2017081860A (ja) * 2015-10-29 2017-05-18 株式会社トクヤマ セレコキシブの製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
EP0859642A2 (fr) * 1995-10-17 1998-08-26 G.D. Searle & Co. Procede de detection de la cyclooxygenase-2
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
TR200001872A3 (tr) * 2000-06-26 2002-01-21 Fako Ilaclari A.S 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem.
NZ550907A (en) * 2004-04-01 2010-10-29 Pharmacia & Upjohn Co Llc Crystalline pyrazole derivative with COX-2 inhibitory activity for treating inflammation

Also Published As

Publication number Publication date
CA2562104C (fr) 2010-08-17
TW200536816A (en) 2005-11-16
BRPI0509506A8 (pt) 2017-01-24
CN1938276B (zh) 2011-08-10
WO2005095349A1 (fr) 2005-10-13
KR20060131949A (ko) 2006-12-20
AU2005227745B2 (en) 2008-05-29
EP1742922B1 (fr) 2016-02-03
JP4177883B2 (ja) 2008-11-05
AU2005227745C1 (en) 2009-02-26
US20100093820A1 (en) 2010-04-15
TNSN06313A1 (fr) 2007-12-03
BRPI0509506A (pt) 2007-09-18
CN1938276A (zh) 2007-03-28
EP1742922A1 (fr) 2007-01-17
ZA200607154B (en) 2008-03-26
MA28494B1 (fr) 2007-03-01
DK1742922T3 (en) 2016-04-11
EA008697B1 (ru) 2007-06-29
US7652149B2 (en) 2010-01-26
UA84455C2 (en) 2008-10-27
EA200601601A1 (ru) 2007-02-27
SI1742922T1 (sl) 2016-07-29
JP2007530655A (ja) 2007-11-01
CA2562104A1 (fr) 2005-10-13
NO20064986L (no) 2006-12-21
US20050222240A1 (en) 2005-10-06
IL177711A0 (en) 2006-12-31
PL1742922T3 (pl) 2016-06-30
KR100820511B1 (ko) 2008-04-11
AU2005227745A1 (en) 2005-10-13
NZ550907A (en) 2010-10-29
HUE028811T2 (en) 2017-01-30
ES2565409T3 (es) 2016-04-04
AR048449A1 (es) 2006-04-26

Similar Documents

Publication Publication Date Title
HK1107977A1 (en) Triazole derivative
IL180331A0 (en) 3-carbamoyl - 2 - pyridone derivative
TWI369356B (en) Tetrahydropyridoindole derivatives
EP1847531A4 (fr) Derive de pyrazole
IL190450A0 (en) Substituted pyrazole compounds
EP1790650B1 (fr) Nouveaux dérivés d'imidazoles substitués
IL180481A0 (en) Aryl-pyridine derivatives
IL180044A0 (en) Pyrazole derivatives
IL179736A0 (en) Pyrrazolo-pyrimidine derivatives
IL183140A0 (en) Substituted benzoquinolizine derivatives
IL182585A0 (en) Imidazo-benzodiazepine derivatives
HK1128022A1 (en) Triazole derivatives
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
HK1100775A1 (en) 4-Amino-5-cyanopyrimidine derivatives
GB0414272D0 (en) OsK1 derivatives
IL180889A0 (en) Pyrazole derivative
HK1099755A1 (en) Crystalline pyrazole derivative
ZA200802786B (en) Substituted pyrazole compounds
IL182001A0 (en) 2-acylaminothiazole derivatives
GB0406137D0 (en) Substituted pyrazoles
GB0409502D0 (en) Triazole derivatives
GB0415888D0 (en) Triazole derivatives
GB0408789D0 (en) Triazole derivatives
GB0422397D0 (en) 3-Cyano-Quinoline derivatives
GB0405905D0 (en) Azaquinazoline derivatives